Link Pharma Chem flips to profit as revenue ticks up 8%
A nano-cap with a ₹13 crore market cap posts a modest ₹7.69 lakh profit for FY26.
— 1 earlier story on Link Pharma Chem Ltd. →What's new with Link Pharma Chem Ltd.
- FY26 profit of ₹7.69 lakh compares to a ₹102.73 lakh loss in FY25.
- Annual revenue reached ₹27.43 crore, a 7.9% increase.
- The board re-appointed directors and auditors in a routine annual meeting.
Why this matters for Link Pharma Chem Ltd.
The company has moved out of the red, but the absolute scale of earnings remains negligible for a listed entity. With no new guidance or major contracts announced, this is a procedural disclosure.
What we're watching
- Whether the company can maintain positive margins in FY27.
- Any potential for business expansion beyond current run rates.
- Liquidity levels for such a small-cap stock.
The full read
Link Pharma Chem is back in the black. It reported a net profit of **₹7.69 lakh** for FY26, a sharp reversal from the **₹102.73 lakh** loss seen in FY25.
Revenue for the year climbed **7.9%** to **₹27.43 crore**. Given the firm's miniscule market capitalization of just **₹13 crore**, these figures reflect minor operational shifts rather than any tectonic change in the business model. The board used its meeting to handle standard governance chores, including re-appointing auditors and directors. There is absolutely nothing in this disclosure that suggests a departure from the performance trends already visible in prior quarterly filings. The company remains a nano-cap player with limited scale, and this routine annual report provides no new catalysts for investors to consider.
Questions answered
- How did the company's financial performance change year-over-year?
- Link Pharma Chem swung from a ₹102.73 lakh loss in FY25 to a ₹7.69 lakh profit in FY26.
- Was there any major strategic news in the filing?
- No. The filing covered routine annual results and standard director and auditor re-appointments.